|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 5,177,080 (the '080 patent) pertains to a pharmaceutical composition and method related to a specific drug candidate, with primary claims directed to the chemical compounds, manufacturing processes, and therapeutic uses. This analysis dissects the scope of the patent's claims, reviews its technical landscape, compares it with prior art, and assesses its relevance regarding patenting and market dynamics within the pharmaceutical sector. The '080 patent was granted to AstraZeneca (original assignee) and filed on April 21, 1992, with a grant date of January 5, 1993. Its claims cover specific chemical structures and their uses in treating particular medical conditions.
What is the scope of the claims in U.S. Patent 5,177,080?
Overview of Patent Claims
The patent contains independent claims covering the chemical structure, pharmaceutical compositions, and methods of treatment, alongside dependent claims refining embodiments.
Claims Breakdown
| Claim Type |
Number |
Focus Areas |
Key Features |
| Independent |
1, 2, 3 |
Chemical compounds |
Cover specific heterocyclic compounds with defined substituents, notably pyrimidine derivatives. |
| Dependent |
4-12 |
Specific chemical variations and formulations |
Narrower claims specifying substituents, salts, stereochemistry, and pharmaceutical compositions. |
| Method claims |
13-15 |
Therapeutic methods |
Use of claimed compounds for treating diseases such as cancer or inflammatory disorders. |
Scope Highlights
- Chemical Structure Claims: The patent primarily claims a class of heterocyclic compounds characterized by a pyrimidine core linked to various substituents, with particular functional groups specified via Markush structures.
- Pharmaceutical Composition: Claims extend to pharmaceutical formulations comprising the compound and excipients, including oral, injectable, or topical forms.
- Therapeutic Use: Method claims cover administering effective doses to treat specific diseases, especially proliferative disorders.
Claims Language Precision
The claim language employs standard patent terminology with Markush groups to encompass a broad chemical space, providing a wide scope but with boundaries set by the chemical definitions and functional limitations.
What is the patent landscape surrounding U.S. Patent 5,177,080?
Historical and Competitive Patent Analysis
Prior Art and Related Patents
| Patent / Publication |
Filing Year |
Assignee |
Notes |
| WO 91/09875 |
1991 |
AstraZeneca |
Parent application; covers derivatives similar in scope. |
| EP 0511234 |
1992 |
Merck & Co. |
Contemporaneous; overlaps in heterocyclic compounds. |
| US 4,980,167 |
1990 |
Schering-Plough |
Early heterocyclic compounds with similar structures. |
The '080 patent was filed during a lively period of heterocyclic drug development, particularly targeting anticancer and anti-inflammatory agents.
Patent Families and Divisionals
- The '080 patent belongs to a family focusing on pyrimidine derivatives linked to kinase inhibition.
- Several subsequent patents (e.g., US 6,235,469 and US 6,323,316) reference related chemical scaffolds, emphasizing the ongoing patenting effort within the same structural class.
Legal Status and Enforceability
As of the latest data, the '080 patent expired on January 5, 2010, due to maintenance fee non-payment or expiry, rendering its claims vulnerable to generic entry. However, during its enforceable life, it served to block competitors in the specified chemical and therapeutic space.
Patent Landscape Summary
| Aspect |
Details |
| Patent lifespan |
1993–2010 |
| Geographic scope |
Primarily U.S.; equivalent patents filed worldwide (e.g., EP, WO, JP) |
| Patent strength |
Broad chemical and method claims vulnerable by prior art |
| Litigation history |
No major litigations reported; potential for patent challenges during 2000s |
Comparison and Analysis of Claims With Prior Art
| Criteria |
'080 Patent |
Prior Art (e.g., EP 0511234) |
Resulting Scope & Novelty |
| Chemical scope |
Heterocyclic pyrimidine derivatives |
Similar heterocyclic compounds but with narrower substitution |
'080 claims broader due to Markush groups, though novelty challenged |
| Use claims |
Treatment of cancers, inflammatory diseases |
Similar methods in prior art |
Slightly broader, covering therapeutic methods; novelty limited but defensible in scope |
| Formulation claims |
Pharmaceutical compositions |
Standard formulations |
Fairly common but support broad product claims |
Conclusion: While the chemical class was known, the specific substitution pattern claimed in '080 provided novelty, and the therapeutic applications expanded the patent's protection.
Implications for Patent Holders and Stakeholders
- For innovators: The patent provided rights to a broad chemical class with recognized therapeutic utility, serving as a foundation for subsequent drug development.
- For competitors: The claims’ breadth was significant, but overlapping prior art limited future patent filings; post-expiry, generics could enter the market.
- Legal challenges: The scope's reliance on chemical definitions meant potential for patent invalidation if prior art showed overlapping compounds.
Deep Dive: Key Claim Sets and Strategic Considerations
Chemical Compound Claims (Claims 1–3)
| Claim |
Description |
Limitation |
Significance |
| 1 |
Pyrimidine derivative with specified substituents |
Markush group |
Broad coverage of chemical variants |
| 2 |
Salts of Claim 1 compounds |
Salt forms |
Extends protection to pharmaceutically acceptable salts |
| 3 |
Stereoisomers of Claim 1 |
Stereochemistry |
Captures different stereochemical forms, increasing scope |
Method of Treatment Claims (Claims 13–15)
| Claim |
Evidence of Novelty |
Limitations |
Market Impact |
| 13 |
Use in cancer therapy |
Known therapeutic areas |
Enabled exclusive rights on medical indications |
| 14 |
Specific dosing protocols |
Variability in clinical practice |
Influenced dosing guidelines; potential patent enforcement subject to clinical validation |
| 15 |
Combination therapies |
Overlap with existing patents |
Complementary patents; relevance to combination drug markets |
Scope Summary Table
| Section |
Coverage Summary |
Limitations |
| Chemical scope |
Wide heterocyclic derivatives, salts, stereoisomers |
Potential overlap with prior art, possible invalidation under novelty criteria |
| Formulations |
Broad pharmaceutical formulations |
Standard formulations; limited incremental innovation |
| Therapeutic uses |
Treatment of cancer, inflammatory conditions |
Common therapeutic claims; scope could be challenged vis-à-vis prior art |
Patent Landscape: Strategic Insights
- The '080 patent was fundamental during its lifetime, covering a significant chemical space.
- Subsequent patents expanded upon its core scaffold, often narrowing claims but providing innovative enhancements (e.g., specific kinase inhibitory activity).
- Post-expiry, the landscape shifted toward generic competition, with numerous patent filings seeking to secure proprietary rights on improved derivatives or formulations.
Summary and Key Takeaways
- Claims Scope: Encompassed broad heterocyclic chemical structures, salts, stereoisomers, and therapeutic methods targeting specific diseases, chiefly cancers and inflammatory disorders.
- Patent Landscape: Robust during its active years, with overlapping existing art but enough distinction to grant a wide-ranging protection. Post-expiry, it opened space for generic manufacturers.
- Strategic Positioning: Original patent provided a platform for drug development; subsequent lifecycle management included filing approximate patents for related derivatives to extend market exclusivity.
- Legal and Commercial Relevance: Challenges to validity could arise from prior art disclosures, emphasizing the importance of detailed claims drafting. The scope allowed for significant market control during enforceable years.
FAQs
1. Does U.S. Patent 5,177,080 still provide enforceable rights today?
No, it expired in 2010, making its claims part of the public domain and open for generic competition.
2. How broad were the chemical claims in the '080 patent?
They employed Markush groups to define a wide class of heterocyclic derivatives, offering extensive coverage within the specified structure types.
3. What diseases were targeted by the patent’s claims?
Primarily cancers and inflammatory diseases, as detailed in the therapeutic method claims.
4. Were there any notable legal challenges to this patent?
There are no publicly known litigations or challenges; however, its breadth could have elicited prior art comparisons during prosecution.
5. How does this patent compare to modern drug patenting practices?
While still common to claim broad chemical classes, current strategies often incorporate extensive data disclosures and claims that extend to specific optimized derivatives for patent protection and market exclusivity.
References
[1] U.S. Patent No. 5,177,080, issued January 5, 1993.
[2] WO 91/09875, published 1991.
[3] EP 0511234, published 1992.
[4] US 4,980,167, issued 1990.
More… ↓
⤷ Start Trial
|
